🔗 Permalink

Inventor profile of:

David Koos

City:

La Mesa, California

Country:

United States

Published Applications:

Last publication date:

2024-11-07

Top Assignees for applications by David Koos

The entities that hold a legal rights for patent applications filed by inventor Koos David:

Regen BioPharma, Inc 12 La Mesa, CA United States
Regen Biopharma, Inc. 3 Medina, MN United States
Zander Therapeutics, Inc. 1 Carson City, NV United States
ZANDER THERAPEUTICS, INC. 1 LA MESA, CA United States
SYBLEU INC. 1 CHEYENNE, WY United States
KCL THERAPEUTICS, INC 1 LA MESA, CA United States

Recent patent applications by Koos David

David Koos from La Mesa, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-11-07

US20240366760A1

Human necessities

ACTIVATION OF SURVIVIN-SPECIFIC IMMUNE RESPONSES USING DENDRITIC CELL DERIVED EXOSOMES

#2 | 2024-05-23

US20240165204A1

Human necessities

MODULATION OF TUMOR MICROENVIRONMENT TO AUGMENT EFFICACY OF IMMUNOTHERAPY

#3 | 2024-03-28

US20240100160A1

Human necessities

ENHANCEMENT OF T CELL HOMING TO TUMORS THROUGH AUGMENTATION OF CHEMOKINE RESPONSIVENESS AND ACTIVATION DEPENDENT CHEMOKINE SECRETION

#4 | 2024-03-21

US20240093205A1

Chemistry; metallurgy

DUAL CHECKPOINT INHIBITOR APTAMER BASED THERAPEUTICS

#5 | 2024-02-29

US20240066126A1

Human necessities

COMBINATION THERAPY OF SOLID TUMORS USING CHIMERIC ANTIGEN RECEPTOR CELLS REPRESENTING ADAPTIVE AND INNATE IMMUNITY

#6 | 2024-01-25

US20240024443A1

Human necessities

AUGMENTATION OF SURVIVIN MODIFIED MRNA VACCINE EFFICACY USING DENDRITIC CELLS

#7 | 2022-09-15

US20220290158A1

Chemistry; metallurgy

Suppression of pathological angiogenesis by inhibition of NR2F6

#8 | 2022-06-02

US20220168240A1

Human necessities

CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT

#9 | 2022-02-03

US20220031912A1

Human necessities

QUALITY OF A CELLULAR GRAFT

#10 | 2021-12-30

US20210403866A1

Chemistry; metallurgy

ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL

#11 | 2021-11-18

US20210353755A1

Human necessities

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition

#12 | 2021-10-14

US20210317180A1

Chemistry; metallurgy

NR2F6 INHIBITED CHIMERIC ANTIGEN RECEPTOR CELLS

#13 | 2021-03-04

US20210059962A1

Human necessities

STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY

#14 | 2019-11-28

US20190358224A1

Human necessities

Small molecule modulators of NR2F6 activity

#15 | 2019-01-03

US20190000879A1

Human necessities

Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes

#16 | 2017-12-21

US20170362596A1

Chemistry; metallurgy

Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition

#17 | 2017-10-26

US20170304418A1

Human necessities

Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells

#18 | 2017-08-31

US20170246207A1

Human necessities

Antigen specific mRNA cellular cancer vaccines

#19 | 2017-06-15

US20170166896A1

Chemistry; metallurgy

Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing Agents

#20 | 2017-02-02

US20170029775A1

Chemistry; metallurgy

Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes

#21 | 2016-03-17

US20160074489A1

Human necessities

STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION

#22 | 2015-02-05

US20150037303A1

Human necessities

CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS

#23 | 2014-03-06

US20140065096A1

Human necessities

CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS

InventorID:

675985 ⎘